Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Weekly News Recap #Phispers
US Medicaid
NA
Finished Drug Prices
NA
1. R-667
2. Rg-667
3. Ro-3300074
1. 410528-02-8
2. Rg-667
3. Ro-3300074
4. Sohonos
5. Clm-001
6. Ipn60120
7. R-667
8. R 667
9. Ipn-60120
10. Ro 3300074
11. Ro3300074
12. 4-((1e)-2-(5,5,8,8-tetramethyl-3-(1h-pyrazol-1-ylmethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl)benzoic Acid
13. 4-[(e)-2-[5,5,8,8-tetramethyl-3-(pyrazol-1-ylmethyl)-6,7-dihydronaphthalen-2-yl]ethenyl]benzoic Acid
14. 28k6i5m16g
15. (e)-4-(2-(3-((1h-pyrazol-1-yl)methyl)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoic Acid
16. Benzoic Acid, 4-((1e)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-3-(1h-pyrazol-1-ylmethyl)-2-naphthalenyl)ethenyl)-
17. Palovarotene [usan]
18. Palovarotene [usan:inn]
19. Unii-28k6i5m16g
20. Palovarotene(r 667)
21. Palovarotene (usan/inn)
22. Palovarotene [inn]
23. Palovarotene [jan]
24. Palovarotene [who-dd]
25. Gtpl8276
26. Schembl4658931
27. Chembl2105648
28. Chebi:188559
29. Dtxsid301025696
30. Bcp16664
31. Ex-a3101
32. Who 9025
33. Zb1580
34. Zinc38467831
35. Cs-2031
36. Db12320
37. Ac-36331
38. Hy-14799
39. R667
40. R 667;ro 3300074
41. D09365
42. 528p028
43. A914214
44. Q15708269
45. 4-[(e)-2-(5,5,8,8-tetramethyl-3-pyrazol-1-ylmethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)vinyl]benzoic Acid
Molecular Weight | 414.5 g/mol |
---|---|
Molecular Formula | C27H30N2O2 |
XLogP3 | 6.8 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 5 |
Exact Mass | 414.230728204 g/mol |
Monoisotopic Mass | 414.230728204 g/mol |
Topological Polar Surface Area | 55.1 Ų |
Heavy Atom Count | 31 |
Formal Charge | 0 |
Complexity | 662 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in emphysema.
Treatment of multiple osteochondromas
Treatment of fibrodysplasia ossificans progressiva
R667 is an orally active, gamma selective retinoid agonist that shows promise as a treatment for emhysema.
M - Musculo-skeletal system
M09 - Other drugs for disorders of the musculo-skeletal system
M09A - Other drugs for disorders of the musculo-skeletal system
M09AX - Other drugs for disorders of the musculo-skeletal system
M09AX11 - Palovarotene
Gamma-selective retinoic acid receptor agonist.
NDC Package Code : 69988-0055
Start Marketing Date : 2022-08-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/1)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 65392-3414
Start Marketing Date : 2023-10-13
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Global Sales Information
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Palovarotene manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Palovarotene, including repackagers and relabelers. The FDA regulates Palovarotene manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Palovarotene API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Palovarotene supplier is an individual or a company that provides Palovarotene active pharmaceutical ingredient (API) or Palovarotene finished formulations upon request. The Palovarotene suppliers may include Palovarotene API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Palovarotene as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Palovarotene API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Palovarotene as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Palovarotene and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Palovarotene NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Palovarotene suppliers with NDC on PharmaCompass.
Palovarotene Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Palovarotene GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Palovarotene GMP manufacturer or Palovarotene GMP API supplier for your needs.
A Palovarotene CoA (Certificate of Analysis) is a formal document that attests to Palovarotene's compliance with Palovarotene specifications and serves as a tool for batch-level quality control.
Palovarotene CoA mostly includes findings from lab analyses of a specific batch. For each Palovarotene CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Palovarotene may be tested according to a variety of international standards, such as European Pharmacopoeia (Palovarotene EP), Palovarotene JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Palovarotene USP).
LOOKING FOR A SUPPLIER?